Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [18F]-FEPPA
Miran Kenk(Centre for Addiction and Mental Health), Romina Mizrahi, Jeffrey H. Meyer(Centre for Addiction and Mental Health), Pablo Rusjan(Centre for Addiction and Mental Health), Sylvain Houle, Gary Remington(University of Toronto), Naren P. Rao(National Institute of Mental Health and Neurosciences), Thiviya Selvanathan(University of Toronto), Ivonne Suridjan(AbbVie (United States)), Alan A. Wilson(Centre for Addiction and Mental Health)
Cited by 168
Related Papers
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Changes in Regional Brain Glucose Metabolism Measured With Positron Emission Tomography After Paroxetine Treatment of Major Depression
|American Journal of Psychiatry|2001|700
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
The Construct of Minor and Major Depression in Alzheimer’s Disease
|American Journal of Psychiatry|2005|271
Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging
|Annals of Neurology|2020|186